EPO GMBH – EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE
EPO GmbH – Experimentelle Pharmakologie und Onkologie
13125 Berlin, Germany
EPO (founded in 1997) is a SME with broad expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and diagnostics like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO investigates mechanisms of tumor growth and metastasis, side effects of drugs, drug resistance, alternative formulations (liposomes, nanoparticles), pharmacokinetics/biodistribution, tumorigenicity of genetically engineered cells, engraftment of human hematopoietic progenitors, transplantation of stem cells and detection of occult tumor cells. EPO has research laboratories based on the Biomedical Research Campus Berlin-Buch, with an expanding research group comprising 25 staff currently. EPO has modern laboratories licensed for animal experiments (capacity > 5000) and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth and a well characterized tumor bank of different cancer entities available. The company was repeatedly partner in different research projects and has a clientele of about 100 pharmacological and biotechnological companies.